Logo

Bluestar Genomics: David Mullarkey

Jan 10, 2022

Early cancer detection company Bluestar Genomics has appointed David Mullarkey as CEO. He will also join the company's board of directors. Current acting CEO and CSO Samuel Levy will continue in his role as CSO.

Mullarkey most recently served as president and CEO of DNA sequencing company Omniome, which was acquired by Pacific Biosciences in 2021. Prior to Omniome, Mullarkey served as president and chief operating officer of Ariosa Diagnostics, which was acquired by Roche in 2014. Mullarkey has also held leadership positions at Johnson & Johnson, Eli Lilly, Valeant Pharmaceuticals, and Dow Pharmaceutical Sciences.

Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.